Quizartinib: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

17 May 2024

  • curprev 17:2117:21, 17 May 2024‎ Rithish Nimmagadda talk contribs‎ 8,825 bytes +8,825‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=quizartinib |aOrAn=a |drugClass=a kinase inhibitor |indicationType=treatment |indication=adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. |hasBlackBoxWarning=Yes |adverseReactions=The most common (>20%) adverse reactions, including laboratory abnormalities, are decreased lymphocytes, decreased potassium,..."
Retrieved from "https://www.wikidoc.org/index.php/Quizartinib"